• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Ad hoc announcements pursuant to Art. 53 LR
  • Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028

Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028

13 August 2024
Ad hoc announcements pursuant to Art. 53 LR

Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2024, upgraded guidance for 2024 and mid-term outlook:

  • Revenue of EUR 135.0 million, +2.4% versus H1 2023 or +2.9% at constant currency rates, driven by commercial activities
  • EBITDA of EUR 2.9 million versus EUR -19.4 million with operational improvements leading to a higher utilization and favorable product mix
  • Capex of EUR 20.5 million or 15.2% of revenue (14.7% in H1 2023); advancing capacity expansion projects in Belgium, Sweden, France and the United States; large-scale SPPS capacity on track for production ramp-up to start during H2 2024
  • Upgrade of guidance for the full year 2024: now expecting high single-digit revenue growth versus 2023 at constant currency rates with positive mid single-digit EBITDA margin, operating at a net loss
  • Sharpened growth strategy, taking into consideration large commercial agreements communicated in December 2022 and March 2024, as well as exposure in fast growing therapeutic areas, particularly the emerging GLP-1 market
  • New mid-term outlook: target to double revenue reported for 2023 by 2028; revenue growth projections supported by commitments and supply forecasts of existing customers
  • EBITDA margin expected to approach 25% by 2028, driven by growth initiatives, improving profitability in the existing base business with higher asset utilization and efficiency as well as operating leverage
  • Advanced capacity expansion roadmap, focusing on the potential for modular solutions with plan to build additional capacity in phases, linked to customer projects
  • Capital expenditures of 15% to 20% of revenue required to ensure capacity also beyond 2028
  • Audio webcast and conference call will take place today at 9:30 am CEST

Juan José González, CEO of PolyPeptide: “We made solid progress during H1 2024 with improved profitability and cash flow. In parallel, we undertook further transformational steps to strengthen our organization with additional industrial-scale manufacturing and commercial capabilities. We sharpened our growth strategy to be the most innovative peptides CDMO. The signing of the large commercial agreements communicated earlier anchors the new mid-term outlook: we now target to double revenue reported for 2023 by 2028 with the EBITDA margin approaching 25%.”

[…]

Download PDF (English)
Download PDF (German)

Back to news

Related posts

11 March 2025

PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth


Read more
12 March 2024

PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow


Read more
15 August 2023

Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers